Novo Nordisk Reports 2024 Earnings with $42.13 Billion Revenue and Impressive Profit Margins
On February 5, Novo Nordisk officially released its annual report for 2024, revealing a remarkable revenue of 29.04 billion Danish kroner (approximately $42.13 billion), representing a 25% increase year-on-year. The operating profit also surged to 12.83 billion Danish kroner (around $18.62 billion), reflecting a 25% growth, while net profit reached 10.10 billion Danish kroner (about $14.65 billion), up 21%. Notably, Novo Nordisk's profit margin (operating profit/sales) stands at an impressive 44.19%, far surpassing many American pharmaceutical giants.
Novo Nordisk operates primarily in two business segments: Diabetes and Obesity Care and Rare Diseases. The majority of its revenue comes from the Diabetes and Obesity Care segment, which generated 27.18 billion Danish kroner in sales for 2024, while the Rare Diseases segment contributed only 1.86 billion Danish kroner.
The GLP-1 class of drugs has emerged as Novo Nordisk's biggest revenue driver. Rybelsus (oral semaglutide) achieved sales of 23.30 billion Danish kroner (approximately $3.38 billion), while Ozempic (injectable semaglutide) brought in 120.34 billion Danish kroner (around $17.46 billion). The weight-loss version, Wegovy, also performed well with sales of 58.21 billion Danish kroner (about $8.44 billion). The total sales for semaglutide reached $29.28 billion, showcasing its strong performance, although it has not yet dethroned Keytruda as the new king of drugs. In addition to semaglutide, Novo Nordisk's GLP-1 offerings include the previous generation liraglutide, with Victoza (liraglutide for diabetes) and Saxenda (liraglutide for weight loss) generating 5.48 billion Danish kroner (approximately $795 million) and 6.94 billion Danish kroner (around $1.01 billion), respectively.
Insulin remains Novo Nordisk's second-largest revenue generator, with total sales of 55.37 billion Danish kroner (approximately $8.03 billion) in 2024, driven by the success of degludec insulin, which saw a 15.3% increase in sales compared to the previous year. The three long-acting insulins—Tresiba (degludec), Xultophy (degludec/liraglutide), and Levemir (detemir)—achieved sales of 9.91 billion, 4.67 billion, and 4.50 billion Danish kroner, respectively. The two premixed insulins, Ryzodeg (degludec/aspart) and NovoMix (premixed aspart), generated revenues of 4.93 billion and 5.86 billion Danish kroner, respectively, with the former showing growth while the latter declined. Rapid-acting insulins, including Fiasp (ultra-rapid aspart) and NovoRapid (aspart), collectively sold 18.52 billion Danish kroner, an increase of approximately 2.6 billion compared to the previous year. Additionally, Novo Nordisk continues to sell second-generation human insulin, which generated 6.97 billion Danish kroner, although this segment saw a year-on-year decline.
In the Rare Diseases segment, Novo Nordisk's product pipeline primarily includes clotting factors and growth hormones, with total sales of only 1.86 billion Danish kroner, representing a small portion of overall revenue.
Unlike other major international pharmaceutical companies, Novo Nordisk has not pursued large-scale acquisitions and maintains a research and development investment intensity of around 15%. However, the company's sustained high revenue growth demonstrates its efficiency in product development. This efficiency can be attributed to four key factors: a strong focus on diabetes, extensive knowledge accumulation over a century, a commitment to user experience, maximizing market value from existing products, and the development of platform technologies. With advanced fatty acid acylation technology, peptide oral delivery technology, and yeast fermentation technology, Novo Nordisk is well-positioned to maintain its competitive edge in the market.
2026-10-30
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Wanhua Chemical's Fujian 800,000 t/y MDI Plant Undergoes Scheduled Maintenance
-
AkzoNobel Rejects €12.5 Billion Offer from Nippon Paint and Sherwin-Williams, Sticks to Merger with Axalta
-
Wanhua Chemical's 240,000-ton/year Iron Phosphate Project Approved
-
Three-Phase Plan for 120,000 Tons! “TPU King” Zhuhai Makes Its Move—Covestro’s New Plant Signals Not Just Capacity Expansion but a Full-Scale Upgrade in the Asia-Pacific Market Battle
-
Pharmaceutical State-Owned Enterprise Acquires Leading Pesticide Company for RMB 5.656 Billion, Betting on Synthetic Biology Industrialization
-
An Explosion Has Occurred in the Jubail Industrial City, Putting 6–8% of Global Petrochemical Production Capacity at Risk
-
Sika Acquires UAE Waterproofing Manufacturer Duproof to Expand Middle East Operations
-
BASF Reportedly Raises Evonik Takeover Proposal to €11.18 Billion
-
BASF increases prices for MDI in ASEAN countries
-
Covestro’s Sudden MDI Price Hike: What’s Really Rising Isn’t $220, but Pricing Power in North America’s Polyurethane Industry
Recommend Reading
-
Evonik Restructures Strategic R&D and Aims to Move Projects into Application Within Five Years
-
$14.5 Billion Solstice–Element Solutions Merger Abruptly Terminated Less Than Two Months After Announcement
-
BASF Technology with CFRP Lands in Nanjing: High-Performance Dispersant Production Line Officially Commissioned
-
BASF and Clariant Exit Quietly! Behind Henkel’s High-Priced Acquisition, Why Did Former Allies Choose to “Let Go”?
-
BASF Raises North American Nylon Products by $0.08/lb, Fourth Price Increase in Six Months
-
Business Society’s Market Outlook for Methanol on August 28, 2026: Weak and Volatile
-
Bullish Factors Support Continued Rise in Adipic Acid Prices in China
-
Business Society’s Market Outlook for Soda Ash on August 27, 2026: Clearly Downward
-
Costs Decline, Phthalic Anhydride Prices Soar and Then Plunge
-
Business Society’s Market Outlook for Gasoline on August 26, 2026: Relatively Strong Consolidation